ClinicalTrials.gg
TerminatedNCT02115386MACS1532Updated Dec 10, 2019Results posted

Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib

A Phase 3 interventional study of Nilotinib in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Terminated at 1 site in Russian Federation. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-10.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated by Novartis

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
57th of 66
7 · median 55
Started
2015
with 4 others
Phase 3
15 of 66
none open now
Registered
50th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 57th largest by enrollment, is one of 5 that started in 2015, is one of 15 in phase 3, and was the 50th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

Primary Objective for this study is to evaluate changes in chronic low grade non-hematological adverse events experienced by patients who have been treated with at least 6 months of imatinib and who have not responded to supportive measures, when they are switched to nilotinib (CTCAE grading system).

Read the detailed description

Study was terminated by Novartis

03

Conditions studied

  • Philadelphia Positive (Ph+) Chronic Myeloid Leukemia

Keywords

  • Ph+ CML, chronic myeloid leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Male or female patients ≥ 18 years of age 2. ≤ 2 3. Diagnosis of CML-CP \< 15% blasts in peripheral blood and bone marrow

  • \< 30% blasts plus promyelocytes in peripheral blood and bone marrow
  • \< 20% basophiles in the peripheral blood
  • ≥ 100 x 109 /L
  • No evidence of extramedullary leukemic involvement, with the exception of hepatosplenomegaly. 4. Minimal treatment duration before inclusion is 6 months. 5. Optimal response to imatinib at the time of inclusion according to LeukemiaNet 2009 criteria defined as:
  • Patients treated with imatinib for ≥6 and \<12 months must be in MCR Patients treated with imatinib for ≥12 and \<18 months must be in CCR
  • Patients treated with imatinib for ≥18 months must be in MMR (MMR response defined either as 3 log reduction of bcr-abl/abl ratio or as 0,1% by IS). 6. Initial treatment with 400mg imatinib with current treatment with imatinib 400 or 300 mg QD 7. Imatinib dose interruptions are allowed prior to inclusion but should not exceed 28 consecutive days 8. Persistent Grade 1- 2 non-hematological adverse events for at least 2 months despite best supportive care. Toxicity was to be evaluated by treating physician using criteria. 9. In case of several types of non-hematological AEs no one can exceed grade 2 and at least one should last at least 2 months. 10. Adequate end organ function defined by:
  • Total \< 1.5 x
  • and ALT \< 2.5 x ULN
  • Creatinine \< 1.5 x ULN
  • Serum amylase and lipase ≤ 1.5x ULN
  • Alkaline phosphatase ≤ 2.5 x ULN unless considered tumor related 11. Serum potassium, magnesium, phosphorus and calcium values within normal range or corrected to within normal limits with supplements prior to first dose of study medication. 12. Patients must have an imatinib of at least 3 days and not to exceed 7 days prior to the first dose of nilotinib. 13. Ability to provide written prior to any study related screening procedures being done

Exclusion criteria

Exclusion criteria:

  1. Patients who have experienced any Grade 3 or higher non-hematologic toxicity 30 days prior to screening
  2. Loss of response (hematologic, cytogenetic, molecular) any time prior to inclusion
  3. Prior accelerated phase or blast phase CML
  4. Previously documented T315I mutation
  5. Chromosomal abnormalities (trisomy 8) and/or clonal evolution other than Ph+.
  6. Previous treatment with imatinib >400 mg any time prior to inclusion.
  7. Previous treatment with any other tyrosine kinase inhibitors except for only imatinib

Impaired cardiac function including any of the following:

  • \< 45% as determined by echocardiogram reading or MUGA
  • Complete left bundle branch block
  • Long syndrome or a known family history of long QT syndrome
  • History or presence of ventricular or atrial tachyarrhythmias
  • Clinically significant resting bradycardia (\< 50 beats per minute)
  • QTcF > 450 msec on baseline . If QTcF > 450 and electrolytes are not within normal ranges, electrolytes were to be corrected and then the patient re-screened for QTcF
  • Myocardial infarction within 1 year of starting study drug
  • Other clinically significant heart disease (e.g., unstable angina, congestive heart failure, or uncontrolled hypertension) 9. Patients receiving therapy with inhibitors of or medications that prolong the QT interval and cannot be either discontinued or switched to a different medication prior to starting study drug. 10. Treatment with strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital, St. John's Wort), that cannot be discontinued or switched to a different medication prior to starting study drug. 11. Impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug. 12. History of acute pancreatitis within 1 year of study entry. 13. Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS involvement, lumbar puncture not required). 14. Any other that is clinically significant or requires active intervention.

    1. Severe or uncontrolled medical conditions (i.e., uncontrolled diabetes, active or uncontrolled infection). 16. Acute or chronic liver or severe renal disease considered unrelated to cancer.
    1. History of significant congenital or acquired bleeding disorder unrelated to cancer.
    1. Previous radiotherapy to ≥ 25% of the bone marrow. 19. Major surgery within 4 weeks prior to Day 1 of study or patients who have not recovered from prior surgery. 20. Treatment with other agents within 30 days of Day 1. 21. History of non-compliance to medical regimens or inability to grant consent 22. Women who are pregnant, breast feeding, or of without a negative urinary test at baseline
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Dosage was 300 mg BID daily taken orally without food.

    Drug: Nilotinib

Interventions

  • supplied in 150 mg capsules to be taken orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 6 Months

    Improvement was defined as decreasing of grade of non-hematological toxicity from 2 to \<2 or from 1 to \<1. In case of multiple low-grade non-hematological toxicities improvement was defined as an improvement of at least one non-hematological AE and no worsening of any other persistent non-hematological AEs.

    Time frame: at 6 month after switching from imatinib to nilotinib

Secondary outcomes

  1. Number of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 3 Months

    Improvement was defined as decreasing of grade of non-hematological toxicity from 2 to \<2 or from 1 to \<1. In case of multiple low-grade non-hematological toxicities improvement was defined as an improvement of at least one non-hematological AE and no worsening of any other persistent non-hematological AEs.

    Time frame: at 3 month after switching from imatinib to nilotinib

  2. Number of Participants With Complete Cytogenetic Response (CCyR)

    Cytogenetic response will be assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases.

    Time frame: at months 6,12 and 24 after switching from imatinib to nilotinib

  3. Number of Participants With a Major Molecular Response

    MMR was defined as a ≥ 3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤ 0.1 % BCR-ABL/ABL % by international scale as measured by RQ-PCR, confirmed by duplicate analysis of the same sample. Molecular response was described for all time points except screening where response was estimated.

    Time frame: Months 1, 3, 6, early termination

  4. Time to and Duration of CCyR and MMR After Switch From Imatinib to Nilotinib at 24 Months

    to evaluate time to achievement and duration of CCyR and MMR after switching from imatinib to nilotinib

    Time frame: at 24 Months

  5. Time to First Improvement of Persistant Chronic Low-grade Non-hematologic AEs at 24 Months After Switch From Imatinib to Nilotinib

    Evaluate time to first improvement of low-grade non-hematologic adverse events, experienced by patients treated with imatinib and persistent despite of best supportive measures after switching to nilotinib therapy. Optimal improvement is defined as AE grade decreasing to 0.

    Time frame: first improvement of AEs after switch to 24 Months

  6. Lisiting by Participant of EORTC-QLQ-C30 for Quality of Life

    EORTC-QLQ-C30 was administered to evaluate quality of life changes after switching to nilotinib. Scores ranged from 1 (very poor) to 6 (excellent)

    Time frame: Screening, months 1, 3, 6, after switch to nilotinib

07

Results

Posted Dec 10, 2019

Participant flow

Participant flow — Overall Study
MilestoneNilotinib
Started7
Completed0
Not completed7
Withdrew: Protocol violation1
Withdrew: Administrative - trial was terminated6

Outcome measures

PrimaryNumber of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 6 Months

Improvement was defined as decreasing of grade of non-hematological toxicity from 2 to \<2 or from 1 to \<1. In case of multiple low-grade non-hematological toxicities improvement was defined as an improvement of at least one non-hematological AE and no worsening of any other persistent non-hematological AEs.

Time frame:
at 6 month after switching from imatinib to nilotinib
Reported as:
Number · participants
Number of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 6 Months
participantsNilotinib
Number of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 6 Months0
SecondaryNumber of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 3 Months

Improvement was defined as decreasing of grade of non-hematological toxicity from 2 to \<2 or from 1 to \<1. In case of multiple low-grade non-hematological toxicities improvement was defined as an improvement of at least one non-hematological AE and no worsening of any other persistent non-hematological AEs.

Time frame:
at 3 month after switching from imatinib to nilotinib
Reported as:
Number · participants
Number of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 3 Months
participantsNilotinib
Number of Participants With Improvement of Grades of Persistent Non-hematological Adverse Event (AE) for Grade 1 and 2 at 3 Months0
SecondaryNumber of Participants With Complete Cytogenetic Response (CCyR)

Cytogenetic response will be assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases.

Time frame:
at months 6,12 and 24 after switching from imatinib to nilotinib
Reported as:
Number · participants
Number of Participants With Complete Cytogenetic Response (CCyR)
participantsNilotinib
Number of Participants With Complete Cytogenetic Response (CCyR)0
SecondaryNumber of Participants With a Major Molecular Response

MMR was defined as a ≥ 3.0 log reduction in BCR-ABL transcripts compared to the standardized baseline or ≤ 0.1 % BCR-ABL/ABL % by international scale as measured by RQ-PCR, confirmed by duplicate analysis of the same sample. Molecular response was described for all time points except screening where response was estimated.

Time frame:
Months 1, 3, 6, early termination
Reported as:
Number · participants
Number of Participants With a Major Molecular Response
participantsNilotinib
Month 15
Month 36
Month 66
Early termination5
SecondaryTime to and Duration of CCyR and MMR After Switch From Imatinib to Nilotinib at 24 Months

to evaluate time to achievement and duration of CCyR and MMR after switching from imatinib to nilotinib

Time frame:
at 24 Months

No measurements were reported for this outcome.

SecondaryTime to First Improvement of Persistant Chronic Low-grade Non-hematologic AEs at 24 Months After Switch From Imatinib to Nilotinib

Evaluate time to first improvement of low-grade non-hematologic adverse events, experienced by patients treated with imatinib and persistent despite of best supportive measures after switching to nilotinib therapy. Optimal improvement is defined as AE grade decreasing to 0.

Time frame:
first improvement of AEs after switch to 24 Months

No measurements were reported for this outcome.

SecondaryLisiting by Participant of EORTC-QLQ-C30 for Quality of Life

EORTC-QLQ-C30 was administered to evaluate quality of life changes after switching to nilotinib. Scores ranged from 1 (very poor) to 6 (excellent)

Time frame:
Screening, months 1, 3, 6, after switch to nilotinib
Reported as:
Number · score
Lisiting by Participant of EORTC-QLQ-C30 for Quality of Life
scoreNilotinib
Patient A Screening3
Patient A Month 13
Patient A Month 33
Patient A Month 63
Patient A early termination3
Patient B screening5
Patient B Month 15
Patient B Month 35
Patient B Month 65
Patient B early termination5
Patient C screening4
Patient C Month 14
Patient C Month 35
Patient C Month 65
Patient C early termination5
Patient D screening3
Patient D Month 13
Patient D Month 33
Patient D Month 63
Patient D early termination4
Patient E screening5
Patient E early termination4
Patient F screening4
Patient F Month 15
Patient F Month 35
Patient F Month 65
Patient F early termination5
Patient G screening5
Patient G Month 14
Patient G Month 35
Patient G Month 65
Patient G early termination5

Adverse events

Collected over Adverse Events and Serious Adverse Events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 9 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib0/7 (0%)0/7 (0%)7/7 (100%)
Most frequent other events
Showing 10 of 17
Most frequent other events
EventNilotinib
HYPOPHOSPHATAEMIAMetabolism and nutrition disorders3/7
LIPASE INCREASEDInvestigations2/7
HYPOACUSISEar and labyrinth disorders1/7
TINNITUSEar and labyrinth disorders1/7
CONSTIPATIONGastrointestinal disorders1/7
DRY MOUTHGastrointestinal disorders1/7
HAEMORRHOIDSGastrointestinal disorders1/7
ASTHENIAGeneral disorders1/7
HYPERBILIRUBINAEMIAHepatobiliary disorders1/7
PHARYNGITISInfections and infestations1/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Nilotinib
Mean47.0 ± 13.1
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female4
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Nilotinib
Caucasian7
08

Study locations

1 site
  • Novartis Investigative Site
    Moscow, 125167, Russian Federation
09

References and documents

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2015 to primary completion in Oct 2016, 10 months.

Results were first posted in Dec 2019, 3 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2014
First posted
Apr 16, 2014
StartActual
Dec 17, 2015
Primary completionActual
Oct 31, 2016
CompletionActual
Oct 31, 2016
Results first posted
Dec 10, 2019
Last update
Dec 10, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02115386
Responsible party
Sponsor
First posted
Apr 16, 2014
Start date
Dec 17, 2015
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016
Results posted
Dec 10, 2019
Last update
Dec 10, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion